BAX and cancer: Despite mechanistic heterogeneity among senescence inducers (i.e., palbociclib, alisertib, doxorubicin, bleomycin, and olaparib) and different genetic backgrounds (i.e., p16-null/p53-proficient, BAX-deficient, and BRCA1-mutant), mitochondrial priming was not universally increased in TIS cancer cells.